Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and preparation method thereof

Abstract

The invention provides a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and a preparation method thereof. Comprising the following components in parts by weight: 5-10 parts of astragalus membranaceus, 5-10 parts of radix paeoniae rubra and 3-5 parts of liquorice. The invention also relates to a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition disclosed by the invention can be used for remarkably improving weight loss of a mouse caused by repeated tracheal stimulation and improving lung function indexes of a COPD mouse, including remarkably increasing TV, PEF, PIF and EF50 values of the COPD mouse and remarkably reducing f, Penh and Ti values, and the treatment effect of a high-dose group is equivalent to that of a positive control drug. In addition, the traditional Chinese medicine composition disclosed by the invention can be used for remarkably inhibiting the expression quantity of IL-6 and TNF-alpha in the COPD mouse alveolar lavage fluid. Therefore, the traditional Chinese medicine composition disclosed by the invention has a remarkable treatment effect on COPD.

Description

Technical Field

[0001] The present invention relates to the technical field of Chinese medicine preparations, and in particular to a Chinese medicine composition for treating chronic obstructive pulmonary disease and a preparation method thereof. Background Art

[0002] Chronic obstructive pulmonary disease (COPD), referred to as COPD, is a major global public health problem. Its epidemiological characteristics are characterized by a large number of patients, high mortality, and heavy socioeconomic burden. It is estimated that from 2020 to 2050, the number of COPD cases in people aged 25 and above will increase by 23% worldwide, and by 2050, there will be nearly 600 million COPD patients worldwide. The prevalence of COPD in people over 40 years old in my country is as high as 8.2%, and the number of patients continues to rise. COPD is mainly caused by smoking, air pollution, occupational dust and chemicals, infection and other factors. These factors lead to chronic inflammatory reactions in the airways and lungs, which in turn cause airway stenosis and airflow limitation. As the disease progresses, the small airways in the lungs will gradually narrow and become blocked, the alveolar elasticity will decrease, and the gas exchange function will be impaired. Western medicine drug treatment mainly focuses on bronchodilators, glucocorticoids, etc., but the efficacy is not ideal, and there are the following shortcomings:

[0003] ① Side effects: Although drugs such as anti-inflammatory drugs, expectorants, hormone drugs, and bronchodilators can relieve COPD symptoms to a certain extent, long-term use may cause side effects of varying degrees. For example, hormone drugs are prone to dependence and drug resistance.

[0004] ② Limited effect: Although drug treatment can temporarily correct hypoxia, it cannot fundamentally solve the problem of airway obstruction and ventilation disorder. The patient's respiratory function continues to decline, making the disease difficult to cure and even worse.

[0005] ③ Treating the symptoms but not the root cause: Most Western medicines can only treat the symptoms of COPD, but cannot deeply regulate the patient's body functions, which makes the disease prone to recurrence.

[0006] ④The cost of long-term treatment is high.

[0007] Despite the emergence of new treatments such as triple inhalation therapy, COPD cannot be completely cured. It can only be treated to alleviate symptoms and delay disease progression. Traditional Chinese medicine has shown unique advantages in the treatment of COPD. Traditional Chinese medicine can improve patients' nutritional status, regulate the body's immunity, reduce inflammation and allergies, relieve pulmonary hypertension, and improve respiratory function through multi-target, multi-link, and multi-pathway conditioning. In the future, with the in-depth study of the mechanism of action of traditional Chinese medicine in the treatment of COPD, traditional Chinese medicine is expected to play a greater role in the treatment of COPD. Summary of the invention

[0008] The purpose of the present invention is to provide a Chinese medicine composition for treating chronic obstructive pulmonary disease and a preparation method thereof.

[0009] The present invention is achieved through the following technical solutions:

[0010] The invention relates to a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease, comprising the following components in weight fractions: 5-10 parts of astragalus, 5-10 parts of red peony root and 3-5 parts of liquorice.

[0011] Preferably, the following components are included in weight fractions: 8 parts of Astragalus, 8 parts of Red Peony Root, and 4 parts of Licorice.

[0012] The present invention also relates to a method for preparing the aforementioned Chinese medicine composition for treating chronic obstructive pulmonary disease, comprising the following steps:

[0013] Step 1, take part of the red peony root, crush it into fine powder, and set aside; then take the astragalus, the remaining red peony root and licorice, add water and boil twice, add 8 times the amount of water for the first time, and add 6 times the amount of water for the second time, each time for 1 hour, combine the decoctions, filter, and concentrate the filtrate to obtain a concentrated solution A;

[0014] Step 2, adding ethanol to the concentrated solution A to make the alcohol content reach 60%, stirring thoroughly, standing for 24 hours, filtering the supernatant, recovering the ethanol until there is no alcohol taste, and continuing to concentrate to obtain concentrated solution B; adding the above-mentioned red peony root powder to the concentrated solution B, mixing, drying, and crushing to obtain a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease.

[0015] Preferably, in step 1, the usage ratio of the part of red peony root to the remaining red peony root is 1:3.

[0016] Preferably, in step 1, the relative density of the concentrated solution A is 1.05-1.15, and the temperature thereof is 80°C.

[0017] Preferably, in step 2, the relative density of the concentrated solution B is 1.35-1.40, and the temperature thereof is 80°C.

[0018] The astragalus in the Chinese medicine composition of the present invention has the effect of strengthening the spleen and tonifying the lungs;

[0019] The red peony root in the Chinese medicine composition of the present invention has multiple pharmacological effects such as anti-endotoxin, anti-thrombosis, anti-platelet aggregation, anti-coagulation, anti-myocardial ischemia, anti-cerebral ischemia, anti-inflammatory, antispasmodic, anti-gastric ulcer, and liver protection;

[0020] The liquorice in the Chinese medicine composition of the present invention has multiple pharmacological effects such as anti-peptic ulcer, liver protection, spasmolysis, anti-arrhythmia, antitussive and expectorant, detoxification, anti-inflammatory, antibacterial, antiviral, anti-allergic, adrenocortical hormone-like effect, anti-tumor, anti-mutation and the like.

[0021] In the Chinese medicine composition of the present invention, astragalus enters the lung and spleen meridians, replenishes the spleen and lung qi, and is the main medicine; red peony root enters the liver and spleen meridians, can dredge blood vessels, dissolve blood stasis, and relieve blood stasis, and is the assistant medicine. Licorice harmonizes the middle and relieves urgency, moistens the lungs, absorbs qi and relieves asthma, detoxifies, and harmonizes various medicines. The present invention combines the three components to form the composition of the present invention, which has the functions of tonifying the lungs, activating blood circulation, and absorbing qi and relieving asthma.

[0022] The present invention has the following advantages:

[0023] (1) The Chinese medicine composition for treating chronic obstructive pulmonary disease of the present invention uses pure natural Chinese medicine ingredients, which greatly reduces the occurrence of side effects and drug resistance.

[0024] (2) The Chinese medicine composition for treating chronic obstructive pulmonary disease of the present invention adopts three kinds of Chinese medicines in combination, among which Astragalus can nourish the middle and replenish Qi, Red Peony Root can invigorate blood circulation and replenish blood, and Licorice can remove phlegm and relieve cough, thus alleviating the efficacy of the medicines; while treating the symptoms, it has the effect of supplementing and repairing the defects of the body and the lesions of the lungs, and has a better improvement and correction effect on the airway blockage and decreased respiratory function of patients with chronic obstructive pulmonary disease.

[0025] (3) The Chinese medicine composition for treating COPD involved in the present invention adopts Chinese medicine for treatment. Chinese medicine has the advantages of multiple components and multiple targets. In addition to the symptoms of COPD, it can also treat by anti-inflammation, repairing damaged tissues, and regulating patient injuries.

[0026] (4) The Chinese medicine composition for treating chronic obstructive pulmonary disease of the present invention adopts three common Chinese medicines in combination, the raw materials are cheap and easily available, the preparation method is simple and feasible, and the treatment cost is greatly reduced.

[0027] (5) The Chinese medicine composition for treating chronic obstructive pulmonary disease of the present invention can significantly improve the lung function indicators of COPD mice, including significantly increasing the tidal volume (TV), expiratory volume per minute (Ti), peak expiratory flow rate (PEF), and Penh and EF50 values ​​of COPD mice, and the therapeutic effect of the high-dose group is equivalent to that of the positive control drug.

[0028] (6) The Chinese medicine composition for treating chronic obstructive pulmonary disease of the present invention can significantly improve the morphology and inflammatory infiltration of the lung tissue of COPD mice, and inhibit the expression of disease marker genes such as TNF-α and IL-6 in the lung tissue of COPD mice, indicating that the Chinese medicine composition of the present invention has a significant therapeutic effect on COPD. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 This is a schematic diagram of the small experiment process;

[0030] Figure 2 is a graph showing weight changes in mice in different groups;

[0031] Figure 3 This is a comparative diagram of the effects of different groups of the present invention on the lung function of mice. DETAILED DESCRIPTION

[0032] The present invention is described in detail below in conjunction with specific embodiments. It should be noted that the following embodiments are only further descriptions of the present invention, but the protection scope of the present invention is not limited to the following embodiments.

[0033] Example 1

[0034] This embodiment relates to a method for preparing a Chinese medicine composition for treating chronic obstructive pulmonary disease, comprising the following steps:

[0035] Step 1, grind 2 parts of red peony root into fine powder for later use, take 8 parts of astragalus, 6 parts of red peony root and 4 parts of licorice, add water and decoct twice, add 8 times of water for the first time and 6 times of water for the second time, each time for 1 hour, combine the decoction, filter, and concentrate the filtrate to a relative density of 1.05-1.15 (80°C);

[0036] Step 2, adding ethanol to make the alcohol content reach 60%, stirring thoroughly, standing for 24 hours, filtering the supernatant, recovering the ethanol until there is no alcohol taste, and continuing to concentrate to a relative density of 1.35-1.40 (80° C.), adding the above-mentioned red peony root powder, mixing, drying, and crushing to obtain a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease.

[0037] Example 2 Pharmacodynamics Experiment Content and Results

[0038] 1. Pharmacodynamics experiment content:

[0039] 1. Experimental Materials

[0040] 1.1 Experimental animals: C57BL / 6 mice, male, 8-10 weeks old, weighing 20-25 g.

[0041] Feeding environment: SPF animal room, environmental conditions controlled at 21℃~25℃, relative humidity 40%~70%, 12-hour light-dark cycle, free diet. After one week of adaptive feeding, modeling began.

[0042] 1.2 Reagents: porcine trypsin (Sigma), lipopolysaccharide (LPS, Escherichia coli O55:B5, Sigma), normal saline, dexamethasone acetate (Zhejiang Xianju Co., Ltd.).

[0043] 1.3 Instruments: micro-syringe, live small animal lung function detection system (EMKA).

[0044] 2. Experimental Methods

[0045] 2.1 Animal grouping and pretreatment

[0046] C57 mice were randomly divided into blank control group, model group, positive drug group, low-dose Chinese medicine group, and high-dose Chinese medicine group, with 10 mice in each group.

[0047] 2.2 Model preparation

[0048] Blank control group: only an equal amount of normal saline was injected into the nasal cavity.

[0049] Model group: porcine trypsin (2U / 50μL / mouse) was injected intranasally on d1, d8, d15, and d21; lipopolysaccharide (7μg / 50μL / mouse) was injected intranasally on d4, d11, d18, and d24.

[0050] Positive drug group: The mice in the model group were injected into the nasal cavity synchronously, and dexamethasone acetate tablets (3 mg / kg / d) were administered orally daily.

[0051] Low-dose Chinese medicine group: The mice in the model group were injected into the nasal cavity synchronously, and the Chinese medicine composition (1.9 g / kg / d) was administered orally daily.

[0052] High-dose Chinese medicine group: The mice in the model group were injected into the nasal cavity synchronously, and the Chinese medicine composition (3.8 g / kg / d) was administered orally daily.

[0053] 2.3 Observation indicators

[0054] Body weight changes: The body weight of mice was measured weekly, and the trend of body weight changes was recorded and analyzed.

[0055] Pulmonary function test: After the experiment, the animal pulmonary function test system was used to measure the airway resistance, lung compliance and other indicators of the mice.

[0056] ELISA kit: ELISA kit is used to determine the levels of TNF-α and IL-6 in mouse serum.

[0057] 2.4 Data processing and statistical analysis

[0058] Graphpad prism software was used for statistical analysis of the data, and the differences in body weight, lung function and pathology between the control group and the experimental group were compared. Statistical methods such as t-test or ANOVA were used, and P < 0.05 was considered statistically significant.

[0059] 2. Results

[0060] 3.1 Physiological conditions of mice

[0061] At the end of the experiment, the mice in the blank group had smooth and shiny fur, even breathing, and no deaths. Two mice in the model group died, and the remaining mice had messy fur, obvious mouth breathing, and rapid breathing. The messy fur of the mice in the positive drug group was significantly better than that of the model group, and their breathing was even. The mice in the group administered with the Chinese medicine combination had significantly smoother and shinier fur, even breathing, and were lively and active than those in the model group. At the end of the experiment, the weight of the mice in the model group was significantly lower than that of the blank group, and the weight of the mice in the three drug-administered groups was significantly higher than that of the model group. Among them, the weight of the high-dose group of the Chinese medicine combination was slightly higher than that of the positive drug group, but there was no significant difference. The results of the weight comparison of different groups are shown in the figure. Figure 1 and Figure 2 shown.

[0062] 3.2 Lung function of mice

[0063] The experimental endpoints were to detect the non-invasive lung function of mice, such as Figure 3 As shown, A is the test for tidal volume (TV), which is the basis for evaluating lung function and ventilation efficiency, and is also an important indicator for displaying lung volume. B is the test for respiratory rate (f), which refers to the number of respiratory cycles completed in 1 minute at rest. C is the test for maximum expiratory volume (PEF), which refers to the instantaneous flow rate when the expiratory flow is the fastest. D is the test for forced expiratory gap (Penh), which is an indicator for quantifying the elasticity of bronchi and trachea and reflects the size of airway resistance. E is the test for inspiratory time (Ti), which refers to the length of time that gas enters the lungs during the respiratory cycle. F is the test for expiratory time (Te), which refers to the time from the start of exhalation to the end of exhalation during the breathing process. G is the test for maximum inspiratory volume (PIF), which refers to the maximum inspiratory flow rate that can be achieved during the inhalation process. H is the test for 50% expiratory flow rate (EF50), which refers to the expiratory flow rate when 50% of the tidal volume is exhaled, which can determine the degree of stenosis of the small airways. Among the above measured indicators, compared with the blank control group, the model group had significantly increased f, Penh, and Ti values ​​of mice (P < 0.01), and significantly decreased TV, PEF, PIF, and EF50 values ​​(P < 0.01). The positive drug group and the low- and high-dose Chinese medicine combination administration groups had significantly improved changes compared with the model group mice (P < 0.05). It is worth mentioning that the f, PEP, and EF50 values ​​of mice in the high-dose Chinese medicine combination administration group were more significantly improved than those in the positive drug group mice, as shown in Figure 2. Figure 3 shown.

[0064] 3.3 Contents of COPD markers in mouse bronchoalveolar lavage fluid

[0065] As shown in Table 1, the levels of TNF-α and IL-6 in the bronchoalveolar lavage fluid of mice in the model group were significantly higher than those in the blank control group. The levels of IL-6 and TNF-α in the bronchoalveolar lavage fluid of mice in the treatment groups given positive drugs and different doses of Chinese medicine compositions were significantly improved compared with those in the model group.

[0066] Table 1

[0067]

[0068]

[0069] The above proves that the Chinese medicine composition of the present invention can significantly improve the weight loss of mice caused by multiple tracheal stimulation, and can improve the lung function indicators of COPD mice, including significantly improving the TV, PEF, PIF and EF50 values ​​of COPD mice, and significantly reducing the f, Penh, Ti values, and the therapeutic effect of the high-dose group is equivalent to that of the positive control drug. In addition, the Chinese medicine composition of the present invention can significantly inhibit the expression of IL-6 and TNF-α in the alveolar lavage fluid of COPD mice. It shows that the Chinese medicine composition of the present invention has a significant therapeutic effect on COPD.

[0070] The above describes the specific embodiments of the present invention. It should be understood that the present invention is not limited to the above specific embodiments, and those skilled in the art may make various modifications or variations within the scope of the claims, which will not affect the essence of the present invention.

Claims

1. A Chinese medicine composition for treating chronic obstructive pulmonary disease, characterized in that: The invention comprises the following components in weight fractions: 5-10 parts of astragalus, 5-10 parts of red peony root and 3-5 parts of liquorice.

2. The Chinese medicine composition for treating chronic obstructive pulmonary disease according to claim 1, characterized in that: The invention comprises the following components in weight fractions: 8 parts of astragalus, 8 parts of red peony root and 4 parts of liquorice.

3. A method for preparing the Chinese medicine composition for treating chronic obstructive pulmonary disease as claimed in claim 1, characterized in that: The following steps are involved: Step 1, take part of the red peony root, crush it into fine powder, and set aside; then take the astragalus, the remaining red peony root and licorice, add water and boil twice, add 8 times the amount of water for the first time, and add 6 times the amount of water for the second time, each time for 1 hour, combine the decoctions, filter, and concentrate the filtrate to obtain a concentrated solution A; Step 2, adding ethanol to the concentrated solution A to make the alcohol content reach 60%, stirring thoroughly, standing for 24 hours, filtering the supernatant, recovering the ethanol until there is no alcohol taste, and continuing to concentrate to obtain concentrated solution B; adding the above-mentioned red peony root powder to the concentrated solution B, mixing, drying, and crushing to obtain a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease.

4. The method for preparing the Chinese medicine composition for treating chronic obstructive pulmonary disease according to claim 3, characterized in that: In step 1, the usage ratio of the part of red peony root to the remaining red peony root is 1:

3.

5. The method for preparing the Chinese medicine composition for treating chronic obstructive pulmonary disease according to claim 3, characterized in that: In step 1, the relative density of the concentrated solution A is 1.05-1.15, and the temperature thereof is 80°C.

6. The method for preparing the Chinese medicine composition for treating chronic obstructive pulmonary disease according to claim 3, characterized in that: In step 2, the relative density of the concentrated solution B is 1.35-1.40, and the temperature thereof is 80°C.

Images